Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Sustained-release fampridine (4-aminopyridine) in multiple sclerosis: efficacy and impact on motor function.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Sustained-release fampridine (4-aminopyridine) in multiple sclerosis: efficacy and impact on motor function.
Sustained-release fampridine (4-aminopyridine) in multiple sclerosis: efficacy and impact on motor function. Drugs R D. 2013 Sep; 13(3):175-81.
View in:
PubMed
subject areas
4-Aminopyridine
4-Aminopyridine
Delayed-Action Preparations
Delayed-Action Preparations
Drug Administration Schedule
Drug Administration Schedule
Exercise Test
Exercise Test
Gait
Gait
Humans
Humans
Male
Male
Middle Aged
Middle Aged
Motor Activity
Motor Activity
Multiple Sclerosis
Multiple Sclerosis
Potassium Channel Blockers
Potassium Channel Blockers
Retrospective Studies
Retrospective Studies
Treatment Outcome
Treatment Outcome
Walking
Walking
authors with profiles
Andrea S Vincent